Globus Medical (GMED) Fundamental Analysis: Revenue, Earnings & Valuation

8.69 / 10

Outperform

Fundamental score is 8.69/10, rated Outperform. Key strengths include high ROE (12.3%), ROA (10.2%), strong profit‑to‑market (Profit‑MV 0.80) and net‑profit ratio (88.9%). Cash‑related metrics are slightly weak, but overall quality remains superior.

Analysis Checks(8/10)

ROA (%)

Value10.19

Score3/3

Weight20.77%

1M Return1.79%

Annualized return on equity (%)

Value12.29

Score3/3

Weight18.86%

1M Return1.64%

Profit-MV

Value0.80

Score2/3

Weight37.27%

1M Return3.26%

Cash-UP

Value-0.12

Score2/3

Weight-33.99%

1M Return-3.92%

Annualized net profit margin on total assets (%)

Value10.19

Score3/3

Weight20.77%

1M Return1.79%

ROE (diluted) (%)

Value11.76

Score3/3

Weight15.80%

1M Return1.39%

Asset-MV

Value-0.55

Score1/3

Weight7.05%

1M Return0.71%

ROE (%)

Value12.29

Score3/3

Weight18.86%

1M Return1.64%

Cash-MV

Value-0.09

Score1/3

Weight-29.30%

1M Return-3.56%

Net profit / Total profit (%)

Value88.89

Score3/3

Weight23.90%

1M Return2.09%

Is GMED fundamentally strong?

GMED scores 8.69/10 on fundamentals and holds a Discounted valuation at present. Backed by its 12.29% ROE, 18.30% net margin, 21.10 P/E ratio, 2.48 P/B ratio, and 423.68% earnings growth, these metrics solidify its Outperform investment rating.